GeoVax Labs Inc
Filed Sep 6, 2024.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Sep 6, 2024
GOVX$0.16-0.1%Stored close · as of Nov 6, 2026
Contents
Summary Compensation Table
The following table sets forth all compensation awarded or earned for employment services during 2023 and 2022 by (i) our chief executive officer, and (ii) our two other most highly compensated executive officers (collectively referred to as the “Named Executive Officers”).
| Name and Principal Position · Year · Salary ($) · Bonus ($) · Option Awards (1) ($) · All Other Compensation ($) · Total ($) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| David A. Dodd | 2023 | $371,000 | $ | - | $ | - | (4) | $13 200 | (7) | $384,200 |
| President and CEO | 2022 | 309,000 | 154,500 | 183,000 | 5,515 | (7) | 652,012 | |||
| Kelly T. McKee, MD (2) | 2023 | 356,367 | - | - | (5) | 4,667 | (7) | 361,034 | ||
| Chief Medical Officer | 2022 | 351,600 | - | 10,980 | - | 362,580 | ||||
| Mark J. Newman, PhD (3) | 2023 | 291,500 | - | - | (6) | - | 291,5004 | |||
| Chief Scientific Officer | 2022 | 254,166 | 110,000 | 73,200 | - | 37,366 | ||||
| (1) | Represents the grant date fair value of the stock options for financial statement reporting purposes. See footnotes 2 and 6 to our consolidated financial statements for the year ended December 31, 2023 for a discussion of the assumptions made and methods used for determining stock compensation values. |
| (2) | Dr. McKee became our Chief Medical Officer effective January 15, 2022 on a part-time consulting basis, becoming a full-time employee effective March 1, 2023. The amounts reported in the table above include payments made to Dr. McKee pursuant to his consulting agreement as well as pursuant to his employment. |
| (3) | Dr. Newman became our Chief Scientific Officer effective August 25, 2020 on a part-time basis, becoming a full-time employee effective March 1, 2022. |
| (4) | Represents the grant date fair value for stock options granted on December 7, 2022 for 16,667 shares with an exercise price of $11.325 per share, vesting over a three-year period. |
| (5) | Represents the grant date fair value for stock options granted on December 7, 2022 for 1,000 shares with an exercise price of $11.325 per share, vesting over a three-year period. |
| (6) | Represents the grant date fair value for stock options granted on December 7, 2022 for 6,667 shares with an exercise price of $11.325 per share, vesting over a three-year period. |
| (7) | Represents employer matching contributions to the Company’s 401(k) retirement plan. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.